Compare AstraZeneca plc (AZN) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Live Nation Entertainment, Inc. — how do they compare? AstraZeneca plc trades at $158.42 (market cap $248.14B), while Live Nation Entertainment, Inc. trades at $184.67 (market cap $42.71B). The key difference: AstraZeneca plc is far larger — about 5.8× Live Nation Entertainment, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| AZN | LYV | |
|---|---|---|
Market Cap | $248.14B | $42.71B |
Sector | Health | Industrials |
52-Week High | $209.48 | $186.59 |
52-Week Low | $147.06 | $125.61 |
Enterprise Value | $275.41B | $44.92B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
LYV trades at $184.64, up 2.2% on the day, with a bullish technical signal from moving averages and strong analyst support (86.96% buy ratings). The company reported Q2 2026 EPS of $1.05, beating estimates, and revenue growth driven by record concert demand. However, valuation metrics like a P/E of 117.49 and negative ROE of -116.65% highlight significant premium pricing and profitability challenges.
Outlook remains positive due to robust live event demand and raised full-year expectations, but risks include high debt, legal uncertainties, and margin pressure. The consensus price target of $209.54 suggests ~13.5% upside, though investors should weigh growth potential against elevated valuation and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
